Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2002

View Archived Issues

Little or no activity for KW-2189 in advanced malignant melanoma

CpG oligodeoxynucleotides may be useful against prion infection

Measurement of BNP levels provides accurate diagnosis of CHF

Fuzeon (T-20) set for launch in 2003

FDA approval for NMP22 BladderChek test

NuGEN Technologies awarded SBIR grant for anthrax test

Lescol sNDA filed for secondary prevention of cardiovascular events in angioplasty patients

FDA approves pediatric labeling of Prevacid

Bruno to market Avanir's docosanol 10% cream in Italy

HE-2200 cleared to enter phase II in patients with elevated cholesterol

Inspire and Discovery collaborate on P2Y12 antagonist program for cardiovascular disease

Pivotal phase III trial of RSR-13 completes enrollment

Approvable letter for lercanidipine

Exelixis and Bristol-Myers Squibb extend drug discovery collaboration

AstraZeneca to provide additional information for Crestor approval

Serono and Genentech sign marketing agreement for Raptiva, formerly Xanelim

Maxim updates Ceplene third quarter progress

Novel GSK-3 inhibitors and their use in diabetes, neurodegeneration, etc.

New antiemetic compound prepared and tested at UCB

Bayer presents new PDE2 inhibitors with utility in dementia

Novel iNOS inhibitor prepared by GSK researchers

Novel HDAC inhibitors identified at Beacon